Last 33.50 GBp
Change Today -0.25 / -0.74%
Volume 603.0K
SPH On Other Exchanges
Symbol
Exchange
OTC US
London
Munich
As of 11:35 AM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

sinclair is pharma plc (SPH) Snapshot

Open
34.75 GBp
Previous Close
33.75 GBp
Day High
34.75 GBp
Day Low
33.25 GBp
52 Week High
11/26/14 - 39.00 GBp
52 Week Low
10/10/14 - 23.50 GBp
Market Cap
166.6M
Average Volume 10 Days
600.3K
EPS TTM
-0.0090 GBp
Shares Outstanding
497.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SINCLAIR IS PHARMA PLC (SPH)

Related News

No related news articles were found.

sinclair is pharma plc (SPH) Related Businessweek News

No Related Businessweek News Found

sinclair is pharma plc (SPH) Details

Sinclair IS Pharma plc, a specialty pharmaceutical company, provides surface technology and delivery systems for aesthetics, wound care, and skin care treatments worldwide. The company’s aesthetic dermatology solutions include Kelo-cote, a topical silicone gel used for the management and prevention of hypertrophic and keloid scars; Kelo-Stretch, which helps in rebuilding damaged collagen and regaining skin elasticity; Sculptra, a volumizer designed to stimulate natural collagen growth; Perfectha for the treatment of wrinkles and facial contours; Ellansé, which offers four dermal filler options for facial aesthetic treatments; and Silhouette Soft, a skin tightening and own collagen stimulator. Its wound care products comprise Flammazine and Flammacerium that are used in the prevention and treatment of severe burns and wounds; and Aloclair Plus for relieving the pain caused by aphthous mouth ulcers and other minor oral lesions. The company’s skin care products include Atopiclair, a non-steroidal topical treatment for the symptomatic relief of atopic, contact allergic, and irritant dermatitis; Papulex, a dermocosmetic product used for cleansing, hydrating, and protecting acne prone skin; Sebclair for the management of skin and scalp seborrhoeic dermatitis; and Bio-Taches products for preventing and reducing pigmentation disorders, such as chloasma, melasma, or dyschromia. Further, it offers other products consisting of Variquel/Haemopressin for the treatment of bleeding oesophageal varices; Aloxi, a 2nd generation 5HT3 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting associated with highly emetogenic chemotherapy and moderately emetogenic chemotherapy; and Decapinol for plaque management. Sinclair IS Pharma plc offers its solutions to hospitals, plastic surgeons, dermatologists, and pharmacists. The company was founded in 1971 and is headquartered in London, the United Kingdom.

161 Employees
Last Reported Date: 10/31/14
Founded in 1971

sinclair is pharma plc (SPH) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: 630.0K GBP
Chief Operating Officer and Director
Total Annual Compensation: 392.0K GBP
Compensation as of Fiscal Year 2014.

sinclair is pharma plc (SPH) Key Developments

Number Of Bidders To Be Lined Up For Sinclair

Minimum of 10 interested parties are believed to show interest in Sinclair IS Pharma plc (AIM:SPH). Sinclair IS Pharma appointed Rothschild to explore means of realizing shareholder value. In other words, find a buyer.

Sinclair IS Pharma plc Appoints Jayne Burrell as Group General Counsel and Company Secretary from 2 January 2015

Sinclair IS Pharma plc announced that Jayne Burrell will join the group from 2 January 2015 as Group General Counsel and Company Secretary. Jayne was previously in the same role at Iceland Foods Limited.

Sinclair Evulates Strategic Options

Sinclair IS Pharma plc (AIM:SPH) (‘Sinclair’) says it is evaluating options including a possible sale. Sinclair said it had decided to appoint N M Rothschild & Sons Ltd. to assist it in evaluating the optimum way to realize the value in the company, which may or may not include the sale of all or part of the company. Sinclair said many of the international companies eyeing it were interested in some form of cooperation, including co-promotion, licensing of products, and merger and acquisition opportunities.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SPH:LN 33.50 GBp -0.25

SPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SPH.
View Industry Companies
 

Industry Analysis

SPH

Industry Average

Valuation SPH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.2x
Price/Book 1.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SINCLAIR IS PHARMA PLC, please visit www.sinclairispharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.